BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 32561638)

  • 1. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study.
    Shen L; Guo J; Zhang Q; Pan H; Yuan Y; Bai Y; Liu T; Zhou Q; Zhao J; Shu Y; Huang X; Wang S; Wang J; Zhou A; Ye D; Sun T; Gao Y; Yang S; Wang Z; Li J; Wu YL
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
    Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
    Frentzas S; Kao S; Gao R; Zheng H; Rizwan A; Budha N; de la Hoz Pedroza L; Tan W; Meniawy T
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
    Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
    Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
    Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
    Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
    Naing A; Gainor JF; Gelderblom H; Forde PM; Butler MO; Lin CC; Sharma S; Ochoa de Olza M; Varga A; Taylor M; Schellens JHM; Wu H; Sun H; Silva AP; Faris J; Mataraza J; Cameron S; Bauer TM
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32179633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
    Bishnoi S; Kotasek D; Aghmesheh M; Yau T; Cosman R; Prawira A; Moore M; Chan SL; Mant A; Eek R; Zielinski R; Su R; Pan Z; Ma Y; Li F; Li P; Tse AN
    Cancer; 2024 Jun; 130(11):1991-2002. PubMed ID: 38404184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
    Patnaik A; Weiss GJ; Rasco DW; Blaydorn L; Mirabella A; Beeram M; Guo W; Lu S; Danaee H; McEachern K; Im E; Sachdev JC
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):93-103. PubMed ID: 34750637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
    Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.
    Harding JJ; Moreno V; Bang YJ; Hong MH; Patnaik A; Trigo J; Szpurka AM; Yamamoto N; Doi T; Fu S; Calderon B; Velez de Mendizabal N; Calvo E; Yu D; Gandhi L; Liu ZT; Galvao VR; Leow CC; de Miguel MJ
    Clin Cancer Res; 2021 Apr; 27(8):2168-2178. PubMed ID: 33514524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC).
    Liu SY; Wu YL
    Expert Opin Investig Drugs; 2020 Dec; 29(12):1355-1364. PubMed ID: 33044117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
    Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
    Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
    Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
    Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
    Mehnert JM; Bergsland E; O'Neil BH; Santoro A; Schellens JHM; Cohen RB; Doi T; Ott PA; Pishvaian MJ; Puzanov I; Aung KL; Hsu C; Le Tourneau C; Hollebecque A; Élez E; Tamura K; Gould M; Yang P; Stein K; Piha-Paul SA
    Cancer; 2020 Jul; 126(13):3021-3030. PubMed ID: 32320048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.
    Rischin D; Migden MR; Lim AM; Schmults CD; Khushalani NI; Hughes BGM; Schadendorf D; Dunn LA; Hernandez-Aya L; Chang ALS; Modi B; Hauschild A; Ulrich C; Eigentler T; Stein B; Pavlick AC; Geiger JL; Gutzmer R; Alam M; Okoye E; Mathias M; Jankovic V; Stankevich E; Booth J; Li S; Lowy I; Fury MG; Guminski A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CX-072 (pacmilimab), a Probody
    Naing A; Thistlethwaite F; De Vries EGE; Eskens FALM; Uboha N; Ott PA; LoRusso P; Garcia-Corbacho J; Boni V; Bendell J; Autio KA; Randhawa M; Durm G; Gil-Martin M; Stroh M; Hannah AL; Arkenau HT; Spira A
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34301809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial.
    D'Angelo SP; Bhatia S; Brohl AS; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Georges S; Shah P; Ellers-Lenz B; Bajars M; Güzel G; Nghiem PT
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.